In short
Clinical trials investigating "[18F]CPFPX" are studying its use in brain imaging for people with drug-resistant epilepsy and healthy volunteers. The main goal is to compare brainstem findings under a breathing-related challenge and learn more about arousal and respiratory control. These studies are in Phase 2 and focus on safety-related research questions and biological markers measured by PET imaging.
Key points
- Clinical trials of "[18F]CPFPX" are looking at brain imaging in neurology, especially in people with drug-resistant epilepsy. The main study compares PET findings in brainstem areas involved in breathing control between patients and healthy subjects. This is a Phase 2 interventional trial with 50 participants. The study uses a hypercapnic condition, which means a breathing challenge with more carbon dioxide. The main result being measured is [18F]-CPFPX BPND in brainstem structures related to respiratory regulation.
Clinical trial overview
The available trial for "[18F]CPFPX" is an interventional study, which means researchers are using a planned test procedure and measuring the results. It is focused on neurology and specifically on people with drug-resistant epilepsy, while also including healthy subjects for comparison.
The study title says it is about the impact of epilepsy on the brainstem adenosine pathway and how this relates to arousal and respiratory reactivity. The brief summary states that the trial compares brain imaging findings with [18F]-CPFPX PET in brainstem structures involved in respiratory regulation under a hypercapnic condition.
Who is being studied
This trial includes patients with drug-resistant epilepsy and healthy subjects. The healthy group is used as a comparison group, so researchers can see whether the brain imaging results are different in epilepsy.
The trial data do not give more detailed eligibility rules, such as age limits or other health requirements. The enrollment is 50 participants in total.
What the study measures
The main outcome is the comparison of [18F]-CPFPX BPND in brainstem structures involved in respiratory regulation under hypercapnic condition in patients with drug-resistant epilepsy and healthy subjects. BPND is a PET scan measurement that helps describe how much tracer is bound in a brain area.
In simple terms, the study is trying to see whether the brainstem pattern seen on PET imaging changes when carbon dioxide levels are increased, and whether this differs between groups. The trial also links these findings to arousal and breathing-related responses.
Study design and phase
The trial is listed as Phase 2. Phase 2 studies are early clinical studies that test how a study procedure performs in people and what it can measure.
The status is Authorised, which means the study has been approved to move forward. The intervention listed is [18F]CPFPX given by injection at 275 MBq.
Why this research matters
This research may help explain how epilepsy affects brain areas that control breathing and alertness. It may also help researchers compare patients with healthy subjects using a brain imaging method that can show differences in specific brainstem structures.
Because the study focuses on a breathing challenge, it is aimed at understanding respiratory regulation, which means how the body keeps breathing stable. The trial does not provide results yet, so its purpose is mainly to measure and compare brain imaging findings.